Dr. John Cush RheumNow
3 years 9 months ago
Xeljanz Cancer Risks Detailed
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
https://t.co/OG2OkD5Tcw https://t.co/1dZcJ5jDUj
Dr. John Cush RheumNow
3 years 9 months ago
Bimekizumab Efficacy in TNF-Refractory PsA
Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors.
https://t.co/NCJvhmisNe https://t.co/Tk2d7ILHl2
Several recent articles inform us of recent trends in Telemedicine.
Dr. John Cush RheumNow
3 years 9 months ago
From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), psoriasis (OR=78.94), erosions (OR=5.74), US +power Doppler (OR=7.11). Neg assoc w/ +RF (OR 0.03), +CCP (OR 0.06). https://t.co/YXcqUq9JCi https://t.co/PLuU6cTDab
Dr. John Cush RheumNow
3 years 9 months ago
3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis assoc w/ diffuse SSc, disease severity (PH, ILD, CVD, GI, renal crisis, myopathy)(OR 2.9- 6.9) & PM/Scl Abs (OR 17.31) https://t.co/ksdPcH9W0O https://t.co/OvI9wytf5H
As the legislative session comes to a close, the American College of Rheumatology (ACR) is calling on members of Congress to include the Improving Seniors’ Timely Access to Care Act (H.R. 3173/S. 3018), the Supporting Medicare Providers Act of 2022 (H.R. 8800), and telehealth protections in any year-end legislative package.
Dr. John Cush RheumNow
3 years 9 months ago
Oligoarticular PsA: FOREMOST Study
Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular PsA: Results from the Ongoing FOREMOST Study
https://t.co/3vkUQnpm9F https://t.co/h5OijjETUk
Dr. John Cush RheumNow
3 years 9 months ago
Sensor-engineered glove evaluates hand function in RA
Dr. David Liew discusses abstract 0904 at ACR22 Convergence. Abstract 0904: Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis
https://t.co/e5VCOC56BC https://t.co/vfuVWMrqSj
Dr. John Cush RheumNow
3 years 9 months ago
Netherlands study of 220 consecutive inflammatory arthritis pts enrolled in electronic remote telehealth monitoring showed that 141 (64%) dropped out, with a median dropout at 17 wks ( moreso in women). Why? Simple is not alway simple... https://t.co/nziKil4vas https://t.co/oyyulMnIu1
Dr. John Cush RheumNow
3 years 9 months ago
National cohort of 20–39-yr old men - among ~1.3 million, 18,473 Dx w/ gout (incidence 3.36/1,000 PY). Developing metabolic syndr doubled #gout risk (aHR 2.31); MetS at all visits had 4x risk (aHR 3.82) & MetS recovery reduced gout risk by 59% https://t.co/bLmf1AL5VI https://t.co/8c47zk6vqu
Dr. John Cush RheumNow
3 years 9 months ago
Top 10 Pharma Revenues 2021:
1 J&J $93.77 billion (USD)
2 Pfizer $81.29 B
3 Roche $68.7 B
4 AbbVie S$56.2 B
5 Novartis $51.63 B
6 Merck $48.7 B
7 BMS $46.4 B
8 GSK $43.57 B
9. Sanofi $44.67 B
10. AstraZeneca $37.47 B
https://t.co/ptFAyk4S5S https://t.co/cCtPboI53x
Dr. John Cush RheumNow
3 years 9 months ago
Goofy or Novel: "How gravity may cause irritable bowel syndrome". A hypothesis, published in the American Journal of Gastroenterology, describes how the intestines, spine, heart, nerves and brain evolved to manage gravity. https://t.co/lLyAkruyyy? https://t.co/TJH8Du8rm6
Dr. John Cush RheumNow
3 years 9 months ago
Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines
Following the 2016 American Academy of Ophthalmology Guidelines, rheums have dutifully reduced the dose of HCQ taken by patients with SLE to some number south of 5mg/kg per day.
https://t.co/iToRttwPbC https://t.co/REpWkI7vC0
Dr. John Cush RheumNow
3 years 9 months ago
A Multidimensional Approach in the Management of Axial Spondylarthritis
Abstract 1510 by Jones et al studied the effect of lifestyle on treatment response in patients with axial spondylarthritis.
https://t.co/Y5syU5cX6Y https://t.co/PO7TZ3ZBOo
